女性性功能障礙治療市場規模、佔有率及成長分析（按藥物、疾病、給藥途徑、分銷管道和地區）－2025-2032 年產業預測

2023 年全球女性性功能障礙治療市場規模為 4.805 億美元，預計將從 2024 年的 5.4297 億美元成長到 2032 年的 14.4344 億美元，預測期內（2025-2032 年）的複合年成長率為 13%。

隨著女性對性健康的認知不斷提高以及尋求醫療干預的意願不斷增強，女性性功能障礙 (FSD) 治療市場正在經歷顯著成長。隨著社會規範的發展以及圍繞女性性行為的討論變得更加開放，圍繞這些問題的恥辱感逐漸消失，為創新治療鋪平了道路。市場促進因素包括女性人口老化，尤其是面臨荷爾蒙相關功能障礙的停經後婦女。各種荷爾蒙療法和非荷爾蒙療法療法的出現，加上個人化醫療和遠端醫療的進步，正在改善治療的機會。儘管有這些正面趨勢，但挑戰依然存在，包括文化禁忌、藥品核准限制和監管障礙。然而，正在進行的臨床研究和對教育和創新的日益關注強烈表明未來市場擴張的潛力。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 臨床試驗
• 管道分析

女性性功能障礙治療市場規模（依藥物類型）

• 市場概覽
• 氟班色林
• 布美拉諾胜肽
• 奧司哌米芬
• 雌激素治療
• 其他

女性性功能障礙治療市場規模（依疾病）

• 市場概覽
• 性慾低下障礙（HSDD）
• 性交時疼痛
• 其他

女性性功能障礙治療市場規模（依給藥途徑）

• 市場概覽
• 口服
• 腸外
• 局部的

女性性功能障礙治療市場規模（依分銷管道）

• 市場概覽
• 醫院藥房
• 藥局和藥房
• 網路藥局

女性性功能障礙治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Millendo Therapeutics（Tempest Therapeutics）
• AbbVie
• TherapeuticsMD
• Sorrento Therapeutics
• Palatin Technologies
• Eureka Therapeutics
• HRA Pharma
• NantKwest
• Bristol-Myers Squibb
• Pfizer
• Allergen
• Bayer
• Neurotrope
• AMAG Pharmaceuticals
• Sprout Pharmaceuticals, Inc.（US）
• Mayne Pharma Group Limited（Australia）
• Millicent Pharma Ltd.（Endoceutics, Inc.）（Ireland）
• Duchesnay Pharmaceutical Group Inc.（Canada）
• Freya Pharma Solutions BV（Netherlands）
• Acerus Pharmaceuticals Corporation（Canada）

結論和建議

Global Female Sexual Dysfunction Treatment Market size was valued at USD 480.5 Million in 2023 and is poised to grow from USD 542.97 Million in 2024 to USD 1443.44 Million by 2032, growing at a CAGR of 13% during the forecast period (2025-2032).

The female sexual dysfunction (FSD) treatment market is witnessing significant growth, driven by rising awareness of sexual health and an increased willingness among women to seek medical interventions. As societal norms evolve and discussions around female sexuality become more open, stigma surrounding these issues diminishes, paving the way for innovative treatments. Key market drivers include an aging female population, particularly postmenopausal women facing hormonal-related dysfunction. The availability of diverse hormonal and non-hormonal therapies, coupled with advancements in personalized medicine and telemedicine, enhances access to treatment. Despite these positive trends, challenges like cultural taboos, limited medication approvals, and regulatory hurdles persist. However, ongoing clinical research and a growing focus on education and innovation signal strong potential for future market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Female Sexual Dysfunction Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Female Sexual Dysfunction Treatment Market Segments Analysis

The global Female Sexual Dysfunction (FSD) Treatment market is segmented by drug, disorder, route of administration, and distribution channel. Key drugs include Flibanserin, Bremelanotide, Ospemifene, and Estrogen Therapy, with hormonal and non-hormonal therapies gaining traction. Major disorders treated are Hypoactive Sexual Desire Disorder (HSDD) and Dyspareunia. Oral administration leads due to convenience, while topical and parenteral options are growing. Distribution channels include hospital, retail, and online pharmacies, with online platforms expanding rapidly. North America dominates the market, while Asia Pacific shows strong growth driven by rising awareness, digital health adoption, and improved access to treatments across emerging healthcare systems.

Driver of the Global Female Sexual Dysfunction Treatment Market

The demand for treatment of Female Sexual Dysfunction (FSD) is being significantly driven by the growing awareness surrounding women's health issues and the increasing incidence of related conditions, such as symptoms associated with menopause, hormonal imbalances, and dysfunctions stemming from stress. The impact of contemporary lifestyles has led to heightened physical and mental health challenges, prompting healthcare systems and providers to incorporate FSD treatments into comprehensive wellness and preventive care strategies. This trend is especially prominent in areas like corporate wellness, reproductive health, and gynecology, where prioritizing sexual health is recognized as essential for enhancing overall quality of life and ensuring long-term well-being.

Restraints in the Global Female Sexual Dysfunction Treatment Market

The Global Female Sexual Dysfunction (FSD) Treatment market faces notable challenges due to high costs associated with specialist consultations, diagnostic tests, and prescribed medications, many of which insurance plans do not cover. This financial burden is especially pronounced for hormonal therapies, branded medications, and long-term treatment options, creating significant obstacles for patients, particularly in low- and middle-income areas. These cost-related issues can dramatically restrict access to necessary care, discouraging many women from pursuing treatment, which ultimately hinders broader acceptance and growth within the market. Addressing these financial barriers is crucial for improving access to FSD therapies.

Market Trends of the Global Female Sexual Dysfunction Treatment Market

The Global Female Sexual Dysfunction (FSD) Treatment market is witnessing a notable trend towards the integration of telehealth and digital therapeutics. This shift addresses the growing demand for discreet, convenient access to consultations, therapies, and prescriptions, thus overcoming geographic limitations and societal stigma often associated with sexual health issues. The appeal of virtual care aligns with patient expectations for privacy and flexibility, enabling continuous monitoring of treatment progress and personalized adjustments in real-time. As healthcare technology advances, it is anticipated that this trend will further enhance patient engagement and satisfaction, ultimately driving the growth of the FSD treatment market globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Clinical Trial
• Pipeline Analysis

Global Female Sexual Dysfunction Treatment Market Size by Drug & CAGR (2025-2032)

• Market Overview
• Flibanserin
• Bremelanotide
• Ospemifene
• Estrogen Therapy
• Others

Global Female Sexual Dysfunction Treatment Market Size by Disorder & CAGR (2025-2032)

• Market Overview
• Hypoactive Sexual Desire Disorder (HSDD)
• Dyspareunia
• Others

Global Female Sexual Dysfunction Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Topical

Global Female Sexual Dysfunction Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

Global Female Sexual Dysfunction Treatment Market Size & CAGR (2025-2032)

• North America (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • US
  • Canada
• Europe (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (By Drug, By Disorder, By Route of Administration, By Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Millendo Therapeutics (Tempest Therapeutics)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TherapeuticsMD
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sorrento Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Palatin Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eureka Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HRA Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NantKwest
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotrope
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AMAG Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sprout Pharmaceuticals, Inc. (U.S.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayne Pharma Group Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Millicent Pharma Ltd. (Endoceutics, Inc.) (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Duchesnay Pharmaceutical Group Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freya Pharma Solutions B.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acerus Pharmaceuticals Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations